Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in Pseudomonas aeruginosa

Front Cell Infect Microbiol. 2024 Jan 17:13:1280265. doi: 10.3389/fcimb.2023.1280265. eCollection 2023.

Abstract

Background: Bacteriophage therapy is becoming part of mainstream Western medicine since antibiotics of clinical use tend to fail. It involves applying lytic bacteriophages that self-replicate and induce cell lysis, thus killing their hosts. Nevertheless, bacterial killing promotes the selection of resistant clones which sometimes may exhibit a decrease in bacterial virulence or antibiotic resistance.

Methods: In this work, we studied the Pseudomonas aeruginosa lytic phage φDCL-PA6 and its variant φDCL-PA6α. Additionally, we characterized and evaluated the production of virulence factors and the virulence in a Galleria mellonella model of resistant mutants against each phage for PA14 and two clinical strains.

Results: Phage φDCL-PA6α differs from the original by only two amino acids: one in the baseplate wedge subunit and another in the tail fiber protein. According to genomic data and cross-resistance experiments, these changes may promote the change of the phage receptor from the O-antigen to the core lipopolysaccharide. Interestingly, the host range of the two phages differs as determined against the Pseudomonas aeruginosa reference strains PA14 and PAO1 and against nine multidrug-resistant isolates from ventilator associated pneumonia.

Conclusions: We show as well that phage resistance impacts virulence factor production. Specifically, phage resistance led to decreased biofilm formation, swarming, and type III secretion; therefore, the virulence towards Galleria mellonella was dramatically attenuated. Furthermore, antibiotic resistance decreased for one clinical strain. Our study highlights important potential advantages of phage therapy's evolutionary impact that may be exploited to generate robust therapy schemes.

Keywords: biofilm; phage resistance; phage therapy; tradeoffs; virulence.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / pharmacology
  • Bacteriophages*
  • Drug Resistance, Microbial
  • Moths*
  • Phage Therapy*
  • Pseudomonas Phages* / genetics
  • Pseudomonas aeruginosa
  • Virulence
  • Virulence Factors / genetics

Substances

  • Virulence Factors
  • Anti-Bacterial Agents

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. JG-C is supported by a master scholarship from CONAHCYT, XR-J by a master scholarship from CONAHCYT, RG-C research is supported by DGAPA, PAPIIT-UNAM grant IN200121, MD-G is supported by the post-doctoral DGAPA UNAM grant. Part of this study was funded by the grant PI19/00878 awarded to MT within the State Plan for R+D+I 2013-2016 (National Plan for Scientific Research, Technological Development, and Innovation 2008-2011) and co-financed by the ISCIII-Deputy General Directorate for Evaluation and Promotion of Research - European Regional Development Fund “A way of Making Europe” and Instituto de Salud Carlos III FEDER. DNA sequencing of the strains was conducted through Sakura Science program (S2022F0200098) which is supported by the Japan Science and Technology Agency.